How many studies have been conducted on Certolizumab Pegol?

BiohacksAI has indexed 291 PubMed studies on Certolizumab Pegol, including 43 randomized controlled trials (RCTs). 73% of studies involve human subjects.

What are the main research areas for Certolizumab Pegol?

The primary research domains for Certolizumab Pegol are 🦴 Bone & Joint, 🔬 Oncology, 🛡️ Immunity. This is based on analysis of 291 PubMed studies using the BiohacksAI evidence platform.

BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.

Certolizumab Pegol

A polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.

291+ PubMed studies analyzed · 43 RCTs · Evidence Score: 55.7

Research Domains

Certolizumab Pegol has been studied across 12 research domains including 🦴 Bone & Joint, 🔬 Oncology, 🛡️ Immunity, 🔬 Inflammation, ✨ Skin & Hair. The primary research focus is 🦴 Bone & Joint with 49% of studies addressing this area.

Loading evidence profile...

This evidence profile for Certolizumab Pegol is generated deterministically from 291 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.